Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of type 2 diabetes with confirmed HbA1c level \>10% at time of enrollment, regardless of prior or current treatment regimens, or time since diagnosis.~Exclusion Criteria:~1. Age \<18 as the feasibility and safety of this treatment regimen should be first established in the adult population; if successful, a subsequent pediatric study will be proposed;~2. Type 1 diabetes as purposefully withholding meal-time insulin is contraindicated;~3. Clinical state requiring inpatient admission/treatment;~4. Contraindication or strong cautions to any of the study medications:~   1. Creatinine above 1.4 mg/dl for women and 1.5 mg/dl for men (per metformin label)~  2. History of lactic acidosis (per metformin label)~  3. Advanced hepatic or cardiac disease (per metformin label)~  4. Age \>80 years (per metformin label)~  5. Chronic alcohol use (\>14 drinks/week)~  6. History of pancreatitis (per liraglutide label)~  7. Personal or family history of medullary thyroid cancer or MEN syndrome (per liraglutide label)~  8. Pregnancy and lactation (per liraglutide label)~5. Any serious or unstable medical condition as it would interfere with treatment assignment as well as outcome measurement;~6. Any scheduled elective procedures/surgeries;~7. Active infections, including osteomyelitis;~8. Not willing to participate, unable to keep projected appointments, unwillingness to receive injectable treatment; unwillingness to perform 7-point glucose profiles over 2 consecutive days the weeks prior to Randomization (visit 1)and the week prior to visit 6~9. Non English speaking.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control: Metformin, Insulin Detemir, Insulin Aspart (Type: ACTIVE_COMPARATOR): Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
- Metformin, insulin determir, Liraglutide (Type: ACTIVE_COMPARATOR): Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).